Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 270 participants.

Also called NCT04670666

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (planned count) (from the registry)
Sponsor
EMS (from the registry)
Registry
  • NCT NCT04670666
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04670666. Randomized; double masking; primary purpose treatment. Start 2024-11-18 (actual); primary completion 2026-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
MADALENA ASSOCIATION
Intervention (Drug)
METFORMIN
Intervention (Drug)
EMPAGLIFLOZIN + LINAGLIPTIN
Intervention (Other)
MADALENA ASSOCIATION PLACEBO
Intervention (Other)
METFORMIN PLACEBO
Intervention (Other)
EMPAGLIFLOZIN + LINAGLIPTIN PLACEBO
Lead sponsor
EMS (class: industry)

Record details

Record id
cardio:ct-nct04670666
Content hash
f968c1ed6c110085b8525634bfc9d82ffb6cf8a214f1c0ddb80cb130a7d5225a